On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
